PMID: 8591087Nov 1, 1995Paper

Phase I/II dose-escalation study of liarozole in patients with stage D, hormone-refractory carcinoma of the prostate

Annals of Surgical Oncology
E J SeidmonA B Kremer

Abstract

Liarozole binds to the cytochrome P-450-dependent hydroxylating enzymes involved in steroid biosynthesis and retinoic acid catabolism. This phase I study investigated the clinical/endocrine toxicity profile of liarozole and determined the maximally tolerated dose (MTD) in hormone-refractory prostate cancer patients. Groups of five patients were treated with oral liarozole caplets, starting at 37.5 mg twice daily. The dose was doubled for each subsequent group until the MTD was reached, after which, an additional 18 patients were entered into the MTD-1 dose stratum. The long-term safety of liarozole was assessed based on treatment-emergent signs and symptoms and clinically significant laboratory results. Thirty-eight patients were enrolled. The MTD was determined to be 300 mg twice daily. Side effects that defined the MTD included lethargy, somnolence, body rash, and paresthesias. Two deaths occurred during the trial (pneumonia and myocardial infarction). Four patients had a > 50% decrease in prostate-specific antigen (PSA) levels (two at 150 mg, two at 300 mg). Of nine patients with measurable disease, two had partial responses. Liarozole was generally well tolerated with no evidence of adrenal insufficiency. Preliminary eviden...Continue Reading

References

Apr 12, 1979·The New England Journal of Medicine·L A Klein
Aug 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A RitterT J Kinsella
Sep 1, 1992·The Journal of Steroid Biochemistry and Molecular Biology·R De CosterC Bowden
Aug 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D L TrumpV C Jordan
Dec 1, 1987·The American Journal of Medicine·A P Lyss
Jan 1, 1988·Cancer Chemotherapy and Pharmacology·C F RochlitzE C Cadman
Jul 1, 1983·The Journal of Urology·J TrachtenbergA Pont
Apr 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A SellaC J Logothetis
Apr 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W K KellyS D Fossa
Aug 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H I Scher, W K Kelly
Jan 1, 1994·CA: a Cancer Journal for Clinicians·C C BoringS Montgomery
Jan 1, 1993·CA: a Cancer Journal for Clinicians·C C BoringT Tong

❮ Previous
Next ❯

Citations

Nov 3, 2016·Cancer Immunology Research·Hweixian Leong PennyEdgar G Engleman
Feb 23, 2021·Frontiers in Oncology·Ruochen LiuHongjuan Cui

❮ Previous
Next ❯

Related Concepts

Related Feeds

Addison Disease

Addison's disease, also known as primary adrenal insufficiency and hypocortisolism, is a long-term endocrine disorder in which the adrenal glands do not produce enough steroid hormones. Discover the latest research on Addison's disease here.